Cerebrovascular Risk Factors May Increase Risk for Parkinson Disease
Most cerebrovascular risk factors are associated with an increased risk for subsequent diagnosis of Parkinson disease.
Parkinson Disease
CSF α-Synuclein Decreases Early in Drug-Naive Patients With Parkinson Disease
Cerebrospinal fluid (CSF) α-synuclein decreases early in untreated Parkinson disease (PD), yet α-synuclein does not appear to correlate with disease progression. This is according to a study in Movement Disorders. The ongoing, longitudinal study (Parkinson’s Progression Markers Initiative) included newly diagnosed, untreated patients with PD (n=423; mean age, 61.7 years) as well as age- and…
FDA Approves New Adjunct Treatment for Parkinson Disease
The Food and Drug Administration (FDA) has approved Nourianz (istradefylline; Kyowa Kirin) tablets as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
Impulse Control Disorders in Parkinson and REM Sleep Behavior Disorder
Among patients with early Parkinson disease, impulse control behaviors are common in the early stages of the disease, with a significant proportion having symptoms of subsyndromal impulse control disorders.
Effects of Muscle-Targeted Nutritional Support on Parkinsonian Rehabilitation
Among patients with Parkinson disease or parkinsonism undergoing a 30-day multidisciplinary intensive rehabilitation treatment (MIRT), consumption of a twice-daily whey protein-based nutritional supplement enriched with leucine and vitamin D preserved muscle mass and improved lower extremity function.
FDA: Entacapone Not Associated With Increased Prostate Cancer Risk
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Vitamin D Level Significantly Correlated With Falls in Parkinson Disease
In patients with Parkinson disease (PD), vitamin D levels are significantly correlated with falls and some nonmotor symptoms.
FDA Cracks Down on Company Selling CBD Products With Unapproved Therapeutic Claims
The Food and Drug Administration (FDA) has issued a warning letter to Curalef Inc. of Wakefield, Massachusetts for illegally selling unapproved cannabidiol (CBD) products online with unsubstantiated health claims.
Can Sexual Activity Reduce Disability in Men With Early Parkinson Disease?
For male patients with Parkinson disease, sexual activity is associated with lower motor and nonmotor disability.
FDA Accepts Opicapone NDA for Adjunctive Treatment of Parkinson Disease
Neurocrine Biosciences announced that the Food and Drug Administration has accepted the New Drug Application for opicapone.
Next post in Movement Disorders
